Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Paula Spitzler"'
Autor:
Darren A.E. Cross, William Pao, Brian Dougherty, Kenneth S. Thress, Garry Beran, Jonathan R. Dry, Paul D. Smith, Henry Brown, Claire H. Barnes, Elizabeth L. Christey O'Brien, Laura E. Ratcliffe, Ambar Ahmed, Miika J. Ahdesmaki, Sarah J. Ross, Eiki Ichihara, Paula Spitzler, Catherine B. Meador, Paul R. Fisher, Zhongwu Lai, Katherine J. Al-Kadhimi, Aleksandra A. Markovets, Daniel Stetson, Catherine A. Eberlein
Supplementary Figures S1-S6. Comparison of genetic alterations across multiple populations resistant to AZD9291 and other EGFR TKIs (S1); Treatment of resistant populations with AZD9291 (S2); Detection and Validation of a novel NRAS E63K mutation (S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb4e6c977b49eac13fcd6db63ef2879
https://doi.org/10.1158/0008-5472.22405292.v1
https://doi.org/10.1158/0008-5472.22405292.v1
Autor:
Darren A.E. Cross, William Pao, Brian Dougherty, Kenneth S. Thress, Garry Beran, Jonathan R. Dry, Paul D. Smith, Henry Brown, Claire H. Barnes, Elizabeth L. Christey O'Brien, Laura E. Ratcliffe, Ambar Ahmed, Miika J. Ahdesmaki, Sarah J. Ross, Eiki Ichihara, Paula Spitzler, Catherine B. Meador, Paul R. Fisher, Zhongwu Lai, Katherine J. Al-Kadhimi, Aleksandra A. Markovets, Daniel Stetson, Catherine A. Eberlein
Supplementary Methods and References. Description of additional methods and procedures used in the study. Also includes Supplementary References.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f24aa03ffbaaa761e6f982d1a139f5b
https://doi.org/10.1158/0008-5472.22405289.v1
https://doi.org/10.1158/0008-5472.22405289.v1
Autor:
Darren A.E. Cross, William Pao, Brian Dougherty, Kenneth S. Thress, Garry Beran, Jonathan R. Dry, Paul D. Smith, Henry Brown, Claire H. Barnes, Elizabeth L. Christey O'Brien, Laura E. Ratcliffe, Ambar Ahmed, Miika J. Ahdesmaki, Sarah J. Ross, Eiki Ichihara, Paula Spitzler, Catherine B. Meador, Paul R. Fisher, Zhongwu Lai, Katherine J. Al-Kadhimi, Aleksandra A. Markovets, Daniel Stetson, Catherine A. Eberlein
Supplementary Figure Legend. Legends for Supplementary Figures S1-S6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eacdd6d0cdaa93faf5e20c2a48201d1
https://doi.org/10.1158/0008-5472.22405295
https://doi.org/10.1158/0008-5472.22405295
Autor:
Darren A.E. Cross, William Pao, Brian Dougherty, Kenneth S. Thress, Garry Beran, Jonathan R. Dry, Paul D. Smith, Henry Brown, Claire H. Barnes, Elizabeth L. Christey O'Brien, Laura E. Ratcliffe, Ambar Ahmed, Miika J. Ahdesmaki, Sarah J. Ross, Eiki Ichihara, Paula Spitzler, Catherine B. Meador, Paul R. Fisher, Zhongwu Lai, Katherine J. Al-Kadhimi, Aleksandra A. Markovets, Daniel Stetson, Catherine A. Eberlein
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196cc96704df21c02038e4482e23ee0b
https://doi.org/10.1158/0008-5472.c.6506792.v1
https://doi.org/10.1158/0008-5472.c.6506792.v1
Autor:
Darren A.E. Cross, William Pao, Brian Dougherty, Kenneth S. Thress, Garry Beran, Jonathan R. Dry, Paul D. Smith, Henry Brown, Claire H. Barnes, Elizabeth L. Christey O'Brien, Laura E. Ratcliffe, Ambar Ahmed, Miika J. Ahdesmaki, Sarah J. Ross, Eiki Ichihara, Paula Spitzler, Catherine B. Meador, Paul R. Fisher, Zhongwu Lai, Katherine J. Al-Kadhimi, Aleksandra A. Markovets, Daniel Stetson, Catherine A. Eberlein
Supplementary Tables S1-S4. Generation of resistant cell populations (S1); Small molecule inhibitors (S2); IC50 (µM) values from cell growth inhibition assays comparing compound sensitivity between parental and resistant cell populations (S3); Genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ddc42520c3270386638ee0395982e2
https://doi.org/10.1158/0008-5472.22405283.v1
https://doi.org/10.1158/0008-5472.22405283.v1
Autor:
Marc Ladanyi, Maria E. Arcila, Mary Ann Melnick, Caroline Nebhan, Mark G. Kris, Ken Takezawa, Elisa de Stanchina, Xiaoling Song, William Pao, G. J. Riely, Valentina Pirazzoli, Vincent A. Miller, Paula Spitzler, Katerina Politi, Yelena Y. Janjigian, Kadoaki Ohashi
Publikováno v:
Clinical Cancer Research. 18:A23-A23
EGFR mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib. The combination of an irreversible EGFR TKI, afatinib, and the anti-EGFR monoclonal antibody, cetuximab, depletes both ph